Expert Review of Anticancer Therapy This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Treatment optimization in early triple negative breast cancer
Expert Rev Anticancer Ther. 2023 Jul-Dec;23(10):1107-1116. doi: 10.1080/14737140.2023.2268840. Epub 2023 Oct 26.ABSTRACTINTRODUCTION: The treatment of early-stage triple-negative breast cancer (TNBC) has radically changed in recent years. Response to neoadjuvant treatment has provided prognostic information, and the achievement of a pathological complete response (pCR) is associated with improved prognosis. An exact treatment algorithm that embraces the trade-off of efficacy and toxicity in a risk-adapted manner has, however, not been consolidated.AREAS COVERED: In this review, we focused on the current treatments used for...
Source: Expert Review of Anticancer Therapy - October 24, 2023 Category: Cancer & Oncology Authors: Elias Kotteas Luca Boscolo Bielo Carmine Valenza Celeste Santoro Chrysanthi Koukoutzeli Dario Trapani Giuseppe Curigliano Source Type: research

Treatment optimization in early triple negative breast cancer
Expert Rev Anticancer Ther. 2023 Oct 24:1-10. doi: 10.1080/14737140.2023.2268840. Online ahead of print.ABSTRACTINTRODUCTION: The treatment of early-stage triple-negative breast cancer (TNBC) has radically changed in recent years. Response to neoadjuvant treatment has provided prognostic information, and the achievement of a pathological complete response (pCR) is associated with improved prognosis. An exact treatment algorithm that embraces the trade-off of efficacy and toxicity in a risk-adapted manner has, however, not been consolidated.AREAS COVERED: In this review, we focused on the current treatments used for patient...
Source: Expert Review of Anticancer Therapy - October 24, 2023 Category: Cancer & Oncology Authors: Elias Kotteas Luca Boscolo Bielo Carmine Valenza Celeste Santoro Chrysanthi Koukoutzeli Dario Trapani Giuseppe Curigliano Source Type: research

The role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia/lymphoma: challenges, opportunities, and future directions
Expert Rev Anticancer Ther. 2023 Oct 18:1-8. doi: 10.1080/14737140.2023.2271662. Online ahead of print.ABSTRACTINTRODUCTION: Nelarabine is a guanine nucleoside analog and functions to terminate DNA synthesis in dividing cells. Pre-clinical and clinical studies have shown that it preferentially accumulates in T-cells where it exerts its cytotoxic effects. After generations of treatment protocol advances, it has been incorporated into numerous treatment regimens against T-lineage acute lymphoblastic leukemia/lymphoma (T-ALL/LLy). On 8 March 2023, the FDA approved the use of nelarabine for its use in T-ALL due to clear eviden...
Source: Expert Review of Anticancer Therapy - October 18, 2023 Category: Cancer & Oncology Authors: Lane H Miller Kim L Maxa Stuart S Winter Nathan P Gossai Source Type: research

Association between event-free survival and overall survival after neoadjuvant treatment for non-small cell lung cancer: a systematic review and meta-analysis
CONCLUSIONS: We found a strong association between treatment effects for EFS and OS, indicating that improvements in EFS are likely to be predictive of improvements in OS. EFS may therefore be a reliable surrogate for OS after neoadjuvant therapy in r-NSCLC.PMID:37850939 | DOI:10.1080/14737140.2023.2272645 (Source: Expert Review of Anticancer Therapy)
Source: Expert Review of Anticancer Therapy - October 18, 2023 Category: Cancer & Oncology Authors: Gyula Ostoros Robert Hettle Nefeli Georgoulia Mehmet Berktas Pratibha Chander Ignacio Diaz Perez Anne-Marie Couto Christian Eichinger Polly Field Peter Morten Source Type: research

The role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia/lymphoma: challenges, opportunities and future directions
Expert Rev Anticancer Ther. 2023 Oct 18. doi: 10.1080/14737140.2023.2271662. Online ahead of print.ABSTRACTINTRODUCTION: Nelarabine is a guanine nucleoside analog and functions to terminate DNA synthesis in dividing cells. Pre-clinical and clinical studies have shown that it preferentially accumulates in T-cells where it exerts its cytotoxic effects. After generations of treatment protocol advances, it has been incorporated into numerous treatment regimens against T-lineage acute lymphoblastic leukemia/lymphoma (T-ALL/LLy). On 8 March 2023, the FDA approved the use of nelarabine for its use in T-ALL due to clear evidence o...
Source: Expert Review of Anticancer Therapy - October 18, 2023 Category: Cancer & Oncology Authors: Lane H Miller Kim L Maxa Stuart S Winter Nathan P Gossai Source Type: research